⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

ICICIPRULI - Fundamental Analysis: Financial Health & Valuation

Back to List

Rating: 3.8

Last Updated Time : 25 May 26, 12:03 am

Fundamental Rating: 3.8

Stock Code ICICIPRULI Market Cap 75,446 Cr. Current Price 520 ₹ High / Low 707 ₹
Stock P/E 47.1 Book Value 94.0 ₹ Dividend Yield 0.32 % ROCE 8.84 %
ROE 10.7 % Face Value 10.0 ₹ DMA 50 554 ₹ DMA 200 599 ₹
Chg in FII Hold -0.59 % Chg in DII Hold 0.64 % PAT Qtr 609 Cr. PAT Prev Qtr 390 Cr.
RSI 37.2 MACD -8.59 Volume 15,26,814 Avg Vol 1Wk 37,97,058
Low price 489 ₹ High price 707 ₹ PEG Ratio 1.85 Debt to equity 0.19
52w Index 14.5 % Qtr Profit Var 57.6 % EPS 11.0 ₹ Industry PE 72.4

📊 Core Financials

  • Revenue Growth: Quarterly PAT rose to ₹609 Cr from ₹390 Cr, showing strong 57.6% growth.
  • Profit Margins: ROE at 10.7% and ROCE at 8.84% indicate moderate profitability.
  • Debt Ratios: Debt-to-equity of 0.19 reflects low leverage.
  • Cash Flows: Dividend yield of 0.32% provides limited shareholder returns.
  • Return Metrics: EPS of ₹11.0 shows modest earnings power relative to valuation.

💹 Valuation Indicators

  • P/E Ratio: 47.1 vs industry PE of 72.4, suggesting undervaluation relative to peers.
  • P/B Ratio: Price ₹520 vs book value ₹94, trading at ~5.5x book.
  • PEG Ratio: 1.85, indicating growth is priced slightly expensively.
  • Intrinsic Value: Current price below DMA 50 (₹554) and DMA 200 (₹599), showing weak momentum.

🏢 Business Model & Competitive Advantage

ICICI Prudential Life Insurance (ICICIPRULI) operates in life insurance, offering protection, savings, and retirement products. Its competitive advantage lies in strong brand presence, diversified offerings, and bancassurance partnerships. Profitability is moderate, but growth potential remains strong in India’s underpenetrated insurance market.

📈 Entry Zone & Long-Term Guidance

Entry zone looks attractive around ₹500–₹530 given RSI (37.2) and MACD (-8.59) showing oversold conditions. Long-term holding is favorable due to industry growth potential and brand strength, though valuations and modest profitability should be monitored.


✅ Positive

  • Strong quarterly PAT growth (57.6%).
  • Low debt-to-equity ratio (0.19) ensures financial stability.
  • P/E ratio (47.1) below industry average (72.4), suggesting relative undervaluation.

⚠️ Limitation

  • Dividend yield of 0.32% offers limited income.
  • ROE (10.7%) and ROCE (8.84%) are modest compared to peers.
  • Stock trading below DMA 200, reflecting weak technical momentum.

📉 Company Negative News

  • FII holding decreased (-0.59%), showing reduced foreign investor confidence.
  • Valuation multiples remain high relative to earnings power.

📈 Company Positive News

  • DII holding increased (+0.64%), showing strong domestic institutional support.
  • Quarterly PAT surged from ₹390 Cr to ₹609 Cr.

🏭 Industry

The life insurance industry in India is expanding with rising awareness, regulatory support, and demand for protection products. Industry PE at 72.4 is higher than ICICIPRULI’s 47.1, suggesting relative undervaluation. Competition from peers remains strong, but ICICIPRULI benefits from bancassurance and brand leadership.

🔎 Conclusion

ICICIPRULI demonstrates growth potential with strong PAT improvement and undervaluation relative to peers. Entry around ₹500–₹530 is attractive for investors seeking exposure to life insurance growth. Long-term holding is recommended for industry expansion and brand strength, though caution is advised due to modest profitability and weak technical momentum.

Would you like me to also compare ICICIPRULI with peers like HDFC Life, SBI Life, and Max Life to evaluate relative positioning in the life insurance sector?

Technical Analysis
Fundamental Analysis

NIFTY 50 - Fundamental Stock Watchlist

NEXT 50 - Fundamental Stock Watchlist

MIDCAP - Fundamental Stock Watchlist

SMALLCAP - Fundamental Stock Watchlist